A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer

British Journal of Cancer

Volumn 89, Issue 10, 2003, Pages 1843-1848

  Vasey, P A ^a   McMahon, L ^a   Paul, J ^a   Reed, N ^a   Kaye, S B ^b  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Capecitabine; Fluoropyrimidine; Ovarian cancer; Quality of life

Indexed keywords

CA 125 ANTIGEN; CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; MONOTHERAPY; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTPATIENT CARE; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; QUALITY OF LIFE;

EID: 0346121846     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601381     Document Type: Article

References (39)

1. Blackledge G, Lawton F, Redman C, Kelly K (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59: 650-653
2. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92: 1759-1768
3. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493
4. Boehmer CH, Jaeger W (2002) Capecitabine in treatment of platinum-resistant recurrent ovarian cancer. Anticancer Res 22: 439-444
5. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38: 349-358
6. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T (1998) Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 16: 1795-1802
7. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL, the Capecitabine Colorectal Cancer Study Group (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13: 566-575
8. Chi DS, Sabbatini P (2000) Advanced ovarian cancer. Curr Treat Options Oncol 1: 139-146
9. Fumoleau P, Largillier R, Trillet-Lenoir V, Orfeuvre H, Extra JM, Dieras V, Berton-Rigaud D, Lesimple T, Culine S, Montestruc F, Mouri Z, Namer M (2002) Capecitabine (Xeloda®) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: a large phase II study. Proc Am Soc Clin Oncol 21: 62
10. Gadducci A, Conte P, Cianci C, Negri S, Genazzani AR (2001) Treatment options in patients with recurrent ovarian cancer. Anticancer Res 21: 3557-3564
11. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomised phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312-3322
12. Gore ME, Fryatt I, Wiltshaw E, Dawson T (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36: 207-211
13. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282-2292
14. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer Statistics 2002. CA: Cancer J Clin 52: 23-47
15. Kerr DJ, ten Bokkel Huinink WW, Ferry DR, Rea DW, Boussard BM, Oulid-Aissa D, Frings S, Nortier JW (2002) A phase I/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 21: 161
16. Liu G, Franssen E, Fitch M, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110-115
17. Look KY, Muss HB, Blessing JA, Morris M (1995) A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 18: 19-22
18. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J (1998) Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16: 2977-2985
19. Markman M (2002) Role of chemotherapy in the management of ovarian cancer. Expert Rev Anticancer Ther 2: 90-96
20. Markman M, Reichman B, Hakes T, Jones W, Lewis Jr JL, Rubin S, Almadrones L, Hoskins W (1991) Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 9: 1801-1805
21. Meyer T, Nelstrop A, Mahmoudi M, Rustin G (2001) Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 12: 1705-1709
22. Miller K, Rugo H, Cobleigh M, Marcom P, Chap L, Holmes F, Fehrenbacher L, Overmoyer B, Reimann J, Vassel A, Langmuir V (2002) Phase III trial of capecitabine plus bevacizumab versus capecitabine alone in women with previously treated metastatic breast cancer. Breast Cancer Res Treat 76: S37
23. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281
24. O'Shaughnessy J (2002) Clinical experience of capecitabine in metastatic breast cancer. Eur J Cancer 38: S10-S14
25. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823
26. Ozols R (2002) Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 5: 1161-1163
27. Payne SA (1992) A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 35: 1505-1509
28. Pignata S, Ballatori E, Favalli G, Scambia G (2001) Quality of life: gynaecological cancers. Ann Oncol 12: S37-S42
29. Reichardt P, Von Minckwitz G, Lück HJ, Thuss-Patience P, Jonat W, Kölbl H, Kiebak D, Kuhn W, Schindler AE, Floemer F, Frings S, Jänicke F, Mohrmann S (2001) Capecitabine: the new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial. Eur J Cancer 37: S191
30. Rustin GJ, Nelstrop AE, Bentzen SM, Bond SJ, McClean P (2000) Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 18: 1733-1739
31. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H, Lambert HE (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J Clin Oncol 14: 1545-1551
32. Sastre J, Butts C, Cassidy J, Conroy T, DeBraud F, Figer A, Schoeffski P, Tabernero J, Twelves C, Van Cutsem E (2002) Capecitabine-oxaliplatin combination (XELOX), effective 1st line therapy for patients (pts) with metastatic colorectal cancer (MCRC): survival update of an international phase II trial. Ann Oncol 13: S80
33. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC, Heron JF (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15: 2183-2193
34. Thigpen J (2000) Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin Oncol 27: S11-S16
35. Twelves C (2002) Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 38: S15-S20
36. Twelves C, Fumoleau P, Jones SE, Cherubini R, Froimtchuk MJ, Kroener JF, Martin M, Mennel RG, Tang SC, Van Hazel GA, Wigler N, Osoba D (2001) Adding Xeloda (capecitabine) to Taxotere (docetaxel) significantly improves survival without compromising quality of life in patients with metastatic breast cancer. Breast Cancer Res Treat 69: 307
37. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P, the Xeloda Colorectal Cancer Study Group (2001) Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo clinic regimen) in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106
38. van der Burg ME, de Wit R, van Putten WL, Logmans A, Kruit WH, Stoter G, Verweij J (2002) Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 86: 2-4
39. Waldron D, O'Boyle CA, Kearney M, Moriarty M, Carney D (1999) Quality-of-life measurement in advanced breast cancer: assessing the individual. J Clin Oncol 17: 3603-3611